Cormorant Global Healthcare Master Fund, LP bought $7.0M of Corbus Pharmaceuticals (CRBP)
Executed Sep 20 2024, disclosed Sep 24 2024, 4 days later.
Over the 21 trading sessions from the disclosed entry session (Sep 24 2024), the stock returned -8.5% (delay-adjusted); from the execution session (Sep 20 2024), +3.9%. Derived: entry at the session's open, exit at the close 20 sessions later.
Cormorant Global Healthcare Master Fund, LP (Other) filed 1 Form 4 report as a reporting entity in the trailing twelve months (0 purchases, 1 sale), most often in Corbus Pharmaceuticals Holdings, Inc. (CRBP). The largest single filing was $46.8M of MLTX (6,494,151 sh across 4 lots, as filed), executed Sep 29 2025.
Healthcare · Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→